share_log

Context Therapeutics Highlights 2023 Corporate Priorities And Pipeline Milestones; Co. Announces 'ELONA Breast Cancer Trial Open and Enrolled First Patient'

Context Therapeutics Highlights 2023 Corporate Priorities And Pipeline Milestones; Co. Announces 'ELONA Breast Cancer Trial Open and Enrolled First Patient'

上下文治療突出 2023 年企業優先事項和管道里程碑; Co.宣布「ELONA 乳腺癌試驗開放並註冊首位患者」
Benzinga Real-time News ·  2023/01/04 07:34
Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company developing novel treatments for solid tumors, with a primary focus on female cancers, today provided 2022 year-end updates and corporate guidance for 2023.
納斯達克:CNTX)是一家臨牀階段的生物製藥公司,為實體腫瘤開發新的治療方法,主要關注女性癌症。該公司今天提供了2022年的最新年終報告和2023年的公司指導。
"I am proud of the substantial progress the Context team made in 2022. We achieved key corporate milestones including nominating CTIM-76 as our Claudin 6 (CLDN6) bispecific antibody clinical candidate and delivering preliminary data in clinical trials of onapristone extended release (ONA-XR), our highly potent and selective progesterone receptor antagonist," said Martin Lehr, CEO of Context. "In 2023, we will continue to advance ONA-XR across the...
Context首席執行官馬丁·萊爾説:“我為Context團隊在2022年取得的實質性進展感到自豪。我們取得了關鍵的公司里程碑,...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論